| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TENX | Common Stock | Purchase | +2.5K | +656.17% | 2.88K | Aug 8, 2024 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TENX | Pre-Funded Warrant | Purchase | +47.5K | 47.5K | Aug 8, 2024 | Common Stock | 47.5K | $0.01 | Direct | F1, F3 | |||
| transaction | TENX | Warrant | Purchase | +25K | 25K | Aug 8, 2024 | Common Stock | 25K | $4.50 | Direct | F1, F4 | |||
| holding | TENX | Stock Option (right to buy) | 4 | Aug 8, 2024 | Common Stock | 4 | $992.00 | Direct | F5 | |||||
| holding | TENX | Stock Option (right to buy) | 4 | Aug 8, 2024 | Common Stock | 4 | $3,200.00 | Direct | F6 |
| Id | Content |
|---|---|
| F1 | . On August 8, 2024, as part of a private placement of the Issuer's securities, the Reporting Person purchased shares of the Issuer's common stock ("Shares") and a pre-funded warrant to purchase Shares, along with a warrant to purchase Shares, pursuant to the terms of a Securities Purchase Agreement, dated August 6, 2024, by and among the Issuer, Reporting Person and certain other accredited investors. The purchase price for each Share and accompanying warrant (reported in Table II) is $3.00. The purchase price for each pre-funded warrant and accompanying warrant (reported in Table II) is $2.99. |
| F2 | The aggregate number of shares of common stock previously reported as 608,645, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024. |
| F3 | The pre-funded warrant has no expiration date. |
| F4 | The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) ( NCT05983250 ) (the "Topline Data Announcement"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029. |
| F5 | These options were previously reported as covering 5,000 shares at an exercise price of $0.62 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024. |
| F6 | These options were previously reported as covering 6,250 shares at an exercise price of $2.00 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024. |